Nature Search

Construction of a recombinant adeno-associated virus (rAAV) vector expressing murine interleukin-12 (IL-12)

Devchand Paul
Muzaffar H Qazilbash
Kenneth H Cowan
Research24 May 2000
Cancer Gene Therapy

Volume: 7, P: 308-315
Author Correction: Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trial

Yago Nieto
Pinaki Banerjee
Katayoun Rezvani
Amendments and Corrections26 Jun 2025
Nature Medicine

P: 1
Clonal evolution of hematopoietic stem cells after autologous stem cell transplantation

Analysis of whole-genome sequencing data from hematopoietic stem and progenitor cells taken from patients with myeloma shows how treatment shapes clonal architecture and sheds light on the evolution of treatment-related myeloid neoplasms.

Hidetaka Uryu
Koichi Saeki
Koichi Takahashi
ResearchOpen Access01 Jul 2025
Nature Genetics

P: 1-13
Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trial

In this phase 1 trial, patients with heavily pretreated and refractory CD30⁺ lymphoma were safely treated with donor-cord-blood-derived NK cells that were precomplexed with the anti-CD30 and anti-CD16A bispecific antibody AFM13, showing encouraging preliminary clinical response rates.

Yago Nieto
Pinaki Banerjee
Katayoun Rezvani
Research04 Apr 2025
Nature Medicine

Volume: 31, P: 1987-1993
A model for predicting day-100 stem cell transplant-related mortality in AL amyloidosis

Eli Muchtar
Angela Dispenzieri
Morie Gertz
Research24 Feb 2025
Bone Marrow Transplantation

Volume: 60, P: 595-602
Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19⁺ B cell tumors: a phase 1/2 trial

In the final report of a phase 1/2 trial evaluating allogeneic CD19-specific CAR-NK cells armored with IL-15 in patients with CD19⁺ hematologic malignancies, the therapy was shown to be safe and efficacious with distinct cord blood features associated with response.

David Marin
Ye Li
Katayoun Rezvani
ResearchOpen Access18 Jan 2024
Nature Medicine

Volume: 30, P: 772-784
Randomized phase II trial of extracorporeal phototherapy and steroids vs. steroids alone for newly diagnosed acute GVHD

Rohtesh S. Mehta
Roland Bassett
Amin M. Alousi
Research04 Jan 2021
Bone Marrow Transplantation

Volume: 56, P: 1316-1324
Impact of clonal plasma cells in autografts on outcomes in high-risk multiple myeloma patients

Oren Pasvolsky
Denái R. Milton
Muzaffar H. Qazilbash
ResearchOpen Access03 May 2023
Blood Cancer Journal

Volume: 13, P: 1-7
Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial

The phase 3 GENESIS trial reports the superiority of the novel CXCR4 inhibitor motixafortide with G-CSF in mobilizing hematopoietic progenitor cells for autologous stem cell transplantation in multiple myeloma.

Zachary D. Crees
Michael P. Rettig
John F. DiPersio
ResearchOpen Access17 Apr 2023
Nature Medicine

Volume: 29, P: 869-879
Acute graft-versus-host disease is the foremost cause of late nonrelapse mortality

Jeremy L. Ramdial
Rohtesh S. Mehta
Uday Popat
Research12 Apr 2021
Bone Marrow Transplantation

Volume: 56, P: 2005-2012
Allogeneic hematopoietic cell transplantation for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN)

Qaiser Bashir
Denái R. Milton
Naveen Pemmaraju
Research11 Oct 2021
Bone Marrow Transplantation

Volume: 57, P: 51-56
Primary plasma cell leukemia: autologous stem cell transplant in an era of novel induction drugs

Lohith Gowda
Mithun Shah
Muzaffar H. Qazilbash
Research16 Nov 2018
Bone Marrow Transplantation

Volume: 54, P: 1089-1093
Pilot study using post-transplant cyclophosphamide (PTCy), tacrolimus and mycophenolate GVHD prophylaxis for older patients receiving 10/10 HLA-matched unrelated donor hematopoietic stem cell transplantation

Mithun Vinod Shah
Rima M. Saliba
Stefan O. Ciurea
Research18 Oct 2018
Bone Marrow Transplantation

Volume: 54, P: 601-606
Maintenance therapy after second autologous hematopoietic cell transplantation for multiple myeloma. A CIBMTR analysis

Oren Pasvolsky
Moshe Yeshurun
Anita D’Souza
Research04 Oct 2021
Bone Marrow Transplantation

Volume: 57, P: 31-37
High activity of the new myeloablative regimen of gemcitabine/clofarabine/busulfan for allogeneic transplant for aggressive lymphomas

Jeremy Ramdial
Ruitao Lin
Yago Nieto
ResearchOpen Access28 Sept 2024
Bone Marrow Transplantation

Volume: 59, P: 1754-1762
Optimal infused CD34⁺ cell dose in multiple myeloma patients undergoing upfront autologous hematopoietic stem cell transplantation

Oren Pasvolsky
Curtis Marcoux
Muzaffar H. Qazilbash
ResearchOpen Access31 Oct 2024
Blood Cancer Journal

Volume: 14, P: 1-8
A second autologous hematopoietic cell transplantation is a safe and effective salvage therapy in select relapsed or refractory AL amyloidosis patients

Carlyn Rose Tan
Noel Estrada-Merly
Anita D’Souza
Correspondence20 Nov 2021
Bone Marrow Transplantation

Volume: 57, P: 295-298
Multiple myeloma patients with a long remission after autologous hematopoietic stem cell transplantation

Oren Pasvolsky
Zhongya Wang
Muzaffar H. Qazilbash
ResearchOpen Access17 May 2024
Blood Cancer Journal

Volume: 14, P: 1-7
Outcomes of patients with multiple myeloma and 1q gain/amplification receiving autologous hematopoietic stem cell transplant: the MD Anderson cancer center experience

Oren Pasvolsky
Sassine Ghanem
Muzaffar H. Qazilbash
ResearchOpen Access10 Jan 2024
Blood Cancer Journal

Volume: 14, P: 1-8
Mass-Fix better predicts for PFS and OS than standard methods among multiple myeloma patients participating on the STAMINA trial (BMT CTN 0702 /07LT)

Angela Dispenzieri
Amrita Krishnan
David Murray
ResearchOpen Access10 Feb 2022
Blood Cancer Journal

Volume: 12, P: 1-8
Financial toxicity in hematological malignancies: a systematic review

Evguenia Ouchveridze
Rahul Banerjee
Ghulam Rehman Mohyuddin
ResearchOpen Access22 Apr 2022
Blood Cancer Journal

Volume: 12, P: 1-9
KRD vs. VRD as induction before autologous hematopoietic progenitor cell transplantation for high-risk multiple myeloma

Mahmoud R. Gaballa
Junsheng Ma
Muzaffar H. Qazilbash
Research06 May 2022
Bone Marrow Transplantation

Volume: 57, P: 1142-1149
Clinical relevance of MYC/BCL2 expression and cell of origin in patients with diffuse large b-cell lymphoma treated with autologous transplant

Taha Al-Juhaishi
Yingjun Wang
Issa F. Khouri
Research18 May 2023
Bone Marrow Transplantation

Volume: 58, P: 1000-1007
Outcomes of toxoplasmosis after allogeneic hematopoietic stem cell transplantation and the role of antimicrobial prophylaxis

Alexandre E. Malek
Taha Al-Juhaishi
Sairah Ahmed
Correspondence14 Feb 2024
Bone Marrow Transplantation

Volume: 59, P: 699-704
Outcomes of t(11;14) light chain (AL) amyloidosis after autologous stem cell transplantation: benchmark for new therapies

Susan Bal
Noel Estrada-Merly
Anita D’Souza
CorrespondenceOpen Access15 Nov 2023
Blood Cancer Journal

Volume: 13, P: 1-4
Pentostatin therapy for steroid-refractory acute graft versus host disease: identifying those who may benefit

Brittany Knick Ragon
Rohtesh S. Mehta
Amin M. Alousi
Research21 Dec 2017
Bone Marrow Transplantation

Volume: 53, P: 315-325
Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era

Binod Dhakal
Sagar Patel
Anita D’Souza
Research20 Apr 2020
Leukemia

Volume: 34, P: 3338-3347
Correction to: Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era

Binod Dhakal
Sagar Patel
Anita D’Souza
Amendments and Corrections29 Mar 2021
Leukemia

Volume: 35, P: 1828
Correction to: Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era

Binod Dhakal
Sagar Patel
Anita D’Souza
Amendments and Corrections05 Jun 2021
Leukemia

Volume: 35, P: 2141

Search

Filter By:

Search

Quick links